Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the Prognosis

Ching-Yang Wu, Jui-Ying Fu, Ching-Feng Wu, Yun-Hen Liu, Ming-Ju Hsieh, Yi-Cheng Wu, Cheng-Ta Yang, Ying-Huang Tsai, Zhengshan Chen., Ching-Yang Wu, Jui-Ying Fu, Ching-Feng Wu, Yun-Hen Liu, Ming-Ju Hsieh, Yi-Cheng Wu, Cheng-Ta Yang, Ying-Huang Tsai, Zhengshan Chen.

Abstract

According to the National Comprehensive Cancer Network (NCCN) guidelines, treatment plans for nonsmall cell lung cancer are to be based on cancer stage. Cancer staging for patients with resectable disease has been based on pathologic stage instead of preoperative clinical stage. However, the possibility of occult mediastinal lymph node metastases could lead to discrepancy between clinical and pathologic stage. While multi-modality treatments may be beneficial for patients with locally advanced disease, most studies have been based on clinical stage. The aim of this study was to identify the beneficial impact of neoadjuvant therapy and the prognostic value of final pathologic stage in these patients. This study enrolled 530 lung cancer patients who received anatomic resection and mediastinal lymph node dissection at Chang Gung Memorial Hospital from January 2005 through June 2011. All resected specimens were examined by pathologists. Postoperative adjuvant therapies were given according to NCCN guideline recommendations. The clinico-pathologic factors of these patients were collected and analyzed. Patients not receiving neoadjuvant therapy had a better probability of disease-free survival (P < 0.001) and overall survival (P = 0.0005), as well as a lower incidence of early relapse. Patients not receiving neoadjuvant therapy had a better disease-free survival rate in stages IA (P < 0.001), IB (P = 0.002), and IIB (P = 0.0117) from the point of view of final pathologic stage. Patients receiving neoadjuvant therapy may experience a higher incidence of early relapse. Neoadjuvant therapy did not show definite benefits in the disease-free and overall survival rates from the point of view of final pathologic stage. Pathologic stage of nonsmall cell lung cancer patients who presented with resectable disease after neoadjuvant therapy did not predict the prognosis.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
(A) Disease-free survival of all patients (neoadjuvant group vs non-neoadjuvant group). (B) Overall survival of all patients (neoadjuvant group vs non-neoadjuvant group). (C) Relapse pattern of all patients.
FIGURE 2
FIGURE 2
(A) Disease-free survival of pathologic stage IA patients (neoadjuvant group vs non-neoadjuvant group). (B) Overall survival of pathologic stage IA patients (neoadjuvant group vs non-neoadjuvant group). (C) Disease-free survival of pathologic IB patients (neoadjuvant group vs non-neoadjuvant group). (D) Overall survival of pathologic IB patients (neoadjuvant group vs non-neoadjuvant group).
FIGURE 3
FIGURE 3
(A) Disease-free survival of pathologic stage IIA patients (neoadjuvant group vs non-neoadjuvant group). (B) Overall survival of pathologic stage IIA patients (neoadjuvant group vs non-neoadjuvant group). (C) Disease-free survival of pathologic IIB patients (neoadjuvant group vs non-neoadjuvant group). (D) Overall survival of pathologic IIB patients (neoadjuvant group vs non-neoadjuvant group).
FIGURE 4
FIGURE 4
(A) Disease-free survival of pathologic stage IIIA patients (neoadjuvant group vs non-neoadjuvant group). (B) Overall survival of pathologic stage IIIA patients (neoadjuvant group vs non-neoadjuvant group). (C) Disease-free survival of no residual tumor patients (neoadjuvant group vs non-neoadjuvant group). (D) Overall survival of no residual tumor patients (neoadjuvant group vs non-neoadjuvant group).

References

    1. Department of Statistics, Ministry of Health Welfare, Taiwan. Analysis of Major cause of death in year 2012 ( MK101) p.17 .
    1. National Comprehensive Cancer Network Guideline Version 7. 2015 Principle of surgical therapy NSCL-B 1-4. .
    1. Koshy M, Fedewa SA, Malik R, et al. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol 2013; 8:915–922.
    1. Betticher DC, Hsu Schmitz SF, Tötsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003; 21:1752–1759.
    1. Rosell R, Gómez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330:153–158.
    1. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86:673–680.
    1. Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006; 1:611–621.
    1. Berghmans T, Paesmans M, Meert AP, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005; 49:13–23.
    1. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20:247–253.
    1. Pisters KM, Vallières E, Crowley JJ, et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol 2010; 28:1843–1849.
    1. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009; 36:260–271.
    1. Song W-A, Zhou N-K, Wang W, et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer. An updated meta-analysis of 13 randomized control trials. J Thorac Oncol 2010; 5:510–516.
    1. Burdett S, Rydzewska LH, Tierney JF, et al. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014; 383:1561–1571.
    1. Fernandes G, Sucena M, Lombardia E, et al. Non small cell lung cancer—comparison between clinical and pathological staging. Rev Port Pneumol 2006; 12:337–357.
    1. McCann J. PET scans approved for detecting metastatic non-small-cell lung cancer. J Natl Cancer Inst 1998; 21:94–96.90.
    1. Vaz AP, Fernandes G, Souto Moura C, et al. Integrated PET/CT in non small cell lung cancer staging—clinical and pathological agreement. Rev Port Pneumol 2012; 18:109–114.
    1. Chiu CH, Yeh YC, Lin KH, et al. Histological subtypes of lung adenocarcinoma have differential 18F-fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan. J Thorac Oncol 2011; 6:1697–1703.
    1. Poettgen C, Theegarten D, Eberhardt W, et al. Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer. Oncology 2007; 73:316–323.
    1. Rosell R, Gómez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 26:7–14.
    1. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 2010; 28:3138–3145.
    1. Mouillet G, Monnet E, Milleron B, et al. Intergroupe Francophone de Cancérologie Thoracique (IFCT) Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials. J Thorac Oncol 2012; 7:841–849.
    1. Milleron B, Westeel V, Quoix E, et al. Complete response following preoperative chemotherapy for resectable non-small cell lung cancer: accuracy of clinical assessment using the French trial database. Chest 2005; 128:1442–1447.
    1. Hsu PK, Huang HC, Hsieh CC, et al. Effect of formalin fixation on tumor size determination in stage I non-small cell lung cancer. Ann Thorac Surg 2007; 84:1825–1829.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren